Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Classical hematology 1

Conditions

Breast Neoplasms 176Neoplasms 173Carcinoma, Non-Small-Cell Lung 152Prostatic Neoplasms 108Colorectal Neoplasms 105Lung Neoplasms 91Ovarian Neoplasms 82Neoplasm Metastasis 76Multiple Myeloma 72Pancreatic Neoplasms 70Leukemia, Myeloid, Acute 63Endometrial Neoplasms 49Squamous Cell Carcinoma of Head and Neck 47Stomach Neoplasms 45Melanoma 44Lymphoma 44Glioblastoma 42Carcinoma, Renal Cell 42Recurrence 41Brain Neoplasms 41Urinary Bladder Neoplasms 39Carcinoma, Hepatocellular 39Precursor Cell Lymphoblastic Leukemia-Lymphoma 38Sarcoma 37Glioma 36Lymphoma, Non-Hodgkin 35Hematologic Neoplasms 35Leukemia, Lymphocytic, Chronic, B-Cell 34Esophageal Neoplasms 33Small Cell Lung Carcinoma 31

Interventions

thymoglobulin 1fludarabine 1Tacrolimus 1Rituximab 1Mycophenolic Acid 1Dexamethasone 1Cyclophosphamide 1Bortezomib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Thalassemia × 30 days × Clear all
NCT05736419 2026-06-03

A Study of Immune Suppression Treatment for People With Sickle Cell Disease or β-Thalassemia Who Are Going to Receive an Allogeneic Hematopoietic Cell Transplantation (HCT)

Memorial Sloan Kettering Cancer Center

Phase 2 Recruiting
24 enrolled
Classical hematology

Anemia, Sickle Cell, Thalassemia, beta-Thalassemia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡